Literature DB >> 17092742

Ubiquitin-conjugating enzyme E2-25K increases aggregate formation and cell death in polyglutamine diseases.

Remko de Pril1, David F Fischer, Raymund A C Roos, Fred W van Leeuwen.   

Abstract

Polyglutamine diseases are characterized by neuronal intranuclear inclusions of expanded polyglutamine proteins, which are also ubiquitinated, indicating impairment of the ubiquitin-proteasome system. E2-25K (Hip2), an ubiquitin-conjugating enzyme, interacts directly with huntingtin and may mediate ubiquitination of the neuronal intranuclear inclusions in Huntington disease. E2-25K could thus modulate aggregation and toxicity of expanded huntingtin. Here we show that E2-25K is involved in aggregate formation of expanded polyglutamine proteins and polyglutamine-induced cell death. Both a truncated mutant, lacking the catalytic tail domain, as well as a full antisense sequence, reduce aggregate formation. Strikingly, both E2-25K mutants also reduced polyglutamine-induced cell death. In postmortem brain material of both Huntington disease and SCA3, E2-25K staining of polyglutamine aggregates was observed in a subset of neurons bearing intranuclear neuronal inclusions. These results demonstrate that targeting by ubiquitination plays an important role in the pathology of polyglutamine diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17092742     DOI: 10.1016/j.mcn.2006.09.006

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  38 in total

1.  Dynamic imaging by fluorescence correlation spectroscopy identifies diverse populations of polyglutamine oligomers formed in vivo.

Authors:  Monica Beam; M Catarina Silva; Richard I Morimoto
Journal:  J Biol Chem       Date:  2012-06-05       Impact factor: 5.157

2.  The de-ubiquitinating enzyme ataxin-3 does not modulate disease progression in a knock-in mouse model of Huntington disease.

Authors:  Li Zeng; Sara J Tallaksen-Greene; Bo Wang; Roger L Albin; Henry L Paulson
Journal:  J Huntingtons Dis       Date:  2013

3.  Global Proteome and Ubiquitinome Changes in the Soluble and Insoluble Fractions of Q175 Huntington Mice Brains.

Authors:  Karen A Sap; Arzu Tugce Guler; Karel Bezstarosti; Aleksandra E Bury; Katrin Juenemann; Jeroen A A Demmers; Eric A Reits
Journal:  Mol Cell Proteomics       Date:  2019-05-28       Impact factor: 5.911

Review 4.  Implication of altered proteasome function in alcoholic liver injury.

Authors:  Natalia A Osna; Terrence-M Donohue
Journal:  World J Gastroenterol       Date:  2007-10-07       Impact factor: 5.742

Review 5.  Role of ubiquitin protein ligases in the pathogenesis of polyglutamine diseases.

Authors:  Priyanka Dikshit; Nihar Ranjan Jana
Journal:  Neurochem Res       Date:  2007-09-01       Impact factor: 3.996

6.  The Ubiquitin Receptor ADRM1 Modulates HAP40-Induced Proteasome Activity.

Authors:  Zih-Ning Huang; Lu-Shiun Her
Journal:  Mol Neurobiol       Date:  2016-11-05       Impact factor: 5.590

7.  It's all about talking: two-way communication between proteasomal and lysosomal degradation pathways via ubiquitin.

Authors:  Martina P Liebl; Thorsten Hoppe
Journal:  Am J Physiol Cell Physiol       Date:  2016-05-25       Impact factor: 4.249

Review 8.  The ubiquitin-proteasome pathway in Huntington's disease.

Authors:  Steven Finkbeiner; Siddhartha Mitra
Journal:  ScientificWorldJournal       Date:  2008-04-20

Review 9.  Ubiquitin proteolytic system: focus on SUMO.

Authors:  Van G Wilson; Phillip R Heaton
Journal:  Expert Rev Proteomics       Date:  2008-02       Impact factor: 3.940

10.  Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington's disease mice: implications for the ubiquitin-proteasomal and autophagy systems.

Authors:  Haiqun Jia; Ryan J Kast; Joan S Steffan; Elizabeth A Thomas
Journal:  Hum Mol Genet       Date:  2012-09-10       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.